In this edition of The Motley Fool's Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the treatment of high cholesterol. From the impact of generic versions of Pfizer's Lipitor to the most exciting experimental drugs in late-stage clinical trials, cholesterol continues to be an area of focus for pharmaceutical companies and investors.
Max Macaluso and Dave Williamson
Jul 18, 2013 at 11:37AM
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs. Follow @TMFMassimo
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 09/28/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return